In-Silico Approaches to Multi-target Drug Discovery
暂无分享,去创建一个
Boon Chuan Low | Xiao Hua Ma | Chunyan Tan | Yu Zong Chen | Mei Lin Go | Zhe Shi | Yuyang Jiang | Yu Zong Chen | Yuyang Jiang | B. C. Low | Zhe Shi | Chunyan Tan | M. Go | X. H. Ma | X. H. Ma
[1] Susan O'Brien,et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] G. Church,et al. Identifying regulatory networks by combinatorial analysis of promoter elements , 2001, Nature Genetics.
[3] Ming-Li Xiang,et al. Pharmacophore Modelling and Virtual Screening for Identification of New Aurora‐A Kinase Inhibitors , 2008, Chemical biology & drug design.
[4] C. Bacchi,et al. Imatinib treatment for gastrointestinal stromal tumour (GIST) , 2009, Journal of cellular and molecular medicine.
[5] Ram Samudrala,et al. Novel paradigms for drug discovery: computational multitarget screening. , 2008, Trends in pharmacological sciences.
[6] Richard Morphy,et al. The physicochemical challenges of designing multiple ligands. , 2006, Journal of medicinal chemistry.
[7] Marina Kriajevska,et al. Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy. , 2007, Urology.
[8] Subhra Mohapatra,et al. Roscovitine Inhibits Differentiation and Invasion in a Three-Dimensional Skin Reconstruction Model of Metastatic Melanoma , 2007, Molecular Cancer Research.
[9] S. Ramamoorthy,et al. Regulation of monoamine transporters: Influence of psychostimulants and therapeutic antidepressants , 2005, The AAPS Journal.
[10] Adrian L Gill,et al. A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. , 2007, Current topics in medicinal chemistry.
[11] R. A. Etten,et al. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition , 2007, Nature Reviews Cancer.
[12] Yan Tang,et al. CHIR-258: A Potent Inhibitor of FLT3 Kinase in Experimental Tumor Xenograft Models of Human Acute Myelogenous Leukemia , 2005, Clinical Cancer Research.
[13] Tooru Kimura,et al. Structure of the aspartic protease plasmepsin 4 from the malarial parasite Plasmodium malariae bound to an allophenylnorstatine-based inhibitor. , 2006, Acta crystallographica. Section D, Biological crystallography.
[14] Horvath Dragos,et al. Predicting the predictability: a unified approach to the applicability domain problem of QSAR models. , 2009, Journal of chemical information and modeling.
[15] Nick Holford,et al. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. , 2006, Blood.
[16] Luhua Lai,et al. Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. , 2008, Journal of medicinal chemistry.
[17] Yujia Dai,et al. ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. , 2007, Blood.
[18] Fabian Mörchen,et al. Maximum Common Binding Modes (MCBM): Consensus Docking Scoring Using Multiple Ligand Information and Interaction Fingerprints , 2008, J. Chem. Inf. Model..
[19] Ming-Chih Crouthamel,et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity , 2007, Molecular Cancer Therapeutics.
[20] X. H. Liu,et al. Virtual Screening of Abl Inhibitors from Large Compound Libraries by Support Vector Machines , 2009, J. Chem. Inf. Model..
[21] M. Oechsner,et al. COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease , 2002, Journal of Neural Transmission.
[22] Ines Gockel,et al. Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer. , 2008, Oncology reports.
[23] S. Okabe,et al. Characteristics of Dasatinib- and Imatinib-Resistant Chronic Myelogenous Leukemia Cells , 2008, Clinical Cancer Research.
[24] Jia Jia,et al. Comparative analysis of machine learning methods in ligand-based virtual screening of large compound libraries. , 2009, Combinatorial chemistry & high throughput screening.
[25] N. Rahimi,et al. IQGAP1-Dependent Signaling Pathway Regulates Endothelial Cell Proliferation and Angiogenesis , 2008, PloS one.
[26] Felix Deanda,et al. Kinase-Targeted Library Design through the Application of the PharmPrint Methodology , 2008, J. Chem. Inf. Model..
[27] Pascal Furet,et al. Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. , 2008, Blood.
[28] Z. R. Li,et al. A support vector machines approach for virtual screening of active compounds of single and multiple mechanisms from large libraries at an improved hit-rate and enrichment factor. , 2008, Journal of molecular graphics & modelling.
[29] Humberto González Díaz,et al. Unified QSAR and network‐based computational chemistry approach to antimicrobials, part 1: Multispecies activity models for antifungals , 2008, J. Comput. Chem..
[30] D. Sacks,et al. IQGAP proteins are integral components of cytoskeletal regulation , 2003, EMBO reports.
[31] Rolf Müller,et al. Crosstalk of oncogenic and prostanoid signaling pathways , 2004, Journal of Cancer Research and Clinical Oncology.
[32] M. Socinski,et al. Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials. , 2007, Reviews on recent clinical trials.
[33] R. Gozalbes,et al. Development and experimental validation of a docking strategy for the generation of kinase-targeted libraries. , 2008, Journal of medicinal chemistry.
[34] D. Reardon,et al. Targeting multiple kinases in glioblastoma multiforme , 2009 .
[35] Lourdes Santana,et al. Unified QSAR approach to antimicrobials. Part 2: predicting activity against more than 90 different species in order to halt antibacterial resistance. , 2007, Bioorganic & medicinal chemistry.
[36] C. Seyfried,et al. 5-HT reuptake inhibitors with 5-HT(1B/1D) antagonistic activity: a new approach toward efficient antidepressants. , 2000, Journal of medicinal chemistry.
[37] Humberto González-Díaz,et al. Multi-target spectral moments for QSAR and Complex Networks study of antibacterial drugs. , 2009, European journal of medicinal chemistry.
[38] B Xie,et al. Synergistic therapeutic actions of herbal ingredients and their mechanisms from molecular interaction and network perspectives. , 2009, Drug discovery today.
[39] Andreas Bender,et al. "Bayes Affinity Fingerprints" Improve Retrieval Rates in Virtual Screening and Define Orthogonal Bioactivity Space: When Are Multitarget Drugs a Feasible Concept? , 2006, J. Chem. Inf. Model..
[40] Thomas S. Lin,et al. Flavopiridol in chronic lymphocytic leukemia: a concise review. , 2009, Clinical lymphoma & myeloma.
[41] J. Brugge,et al. Activity of the multikinase inhibitor dasatinib against ovarian cancer cells , 2009, British Journal of Cancer.
[42] Hong Chang,et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. , 2004, Blood.
[43] Jeffrey N. Myers,et al. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice , 2007, Molecular Cancer Therapeutics.
[44] Christophe Massard,et al. Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer , 2009, Clinical Cancer Research.
[45] Sang Hoon Lee,et al. In vivo Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer Models , 2005, Clinical Cancer Research.
[46] Xin Huang,et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.
[47] I. Kopin,et al. Monoamine oxidase and catecholamine metabolism. , 1994, Journal of neural transmission. Supplementum.
[48] E. Sausville,et al. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. , 1998, Blood.
[49] K. Shokat,et al. Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 , 2007, Nature.
[50] Ariel Fernández,et al. Turning promiscuous kinase inhibitors into safer drugs. , 2008, Trends in biotechnology.
[51] Jaffer A. Ajani,et al. New Pharmacological Developments in the Treatment of Hepatocellular Cancer , 2012, Drugs.
[52] Andreas Bender,et al. Analysis of Activity Space by Fragment Fingerprints, 2D Descriptors, and Multitarget Dependent Transformation of 2D Descriptors , 2006, J. Chem. Inf. Model..
[53] M. Millan. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. , 2006, Pharmacology & therapeutics.
[54] D. Reardon,et al. Targeting multiple kinases in glioblastoma multiforme. , 2009, Expert opinion on investigational drugs.
[55] Christine Stephan,et al. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. , 2007, Cancer research.
[56] Martin Krug,et al. Recent advances in the development of multi-kinase inhibitors. , 2008, Mini reviews in medicinal chemistry.
[57] A. Senderowicz,et al. Flavopiridol: the First Cyclin-Dependent Kinase Inhibitor in Human Clinical Trials , 2004, Investigational New Drugs.
[58] B. Druker,et al. Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. , 2004, Blood.
[59] M. Gordon,et al. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma , 2008 .
[60] P. Blier,et al. Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors. , 2009, Current drug targets.
[61] G. Sonpavde,et al. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma , 2008, Expert opinion on investigational drugs.
[62] Eugenio Uriarte,et al. Alignment-free prediction of a drug-target complex network based on parameters of drug connectivity and protein sequence of receptors. , 2009, Molecular pharmaceutics.
[63] Christopher M. Overall,et al. Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy , 2006, Nature Reviews Cancer.
[64] M. Verdonk,et al. A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. , 2007, Current topics in medicinal chemistry.
[65] Richard Morphy,et al. The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds. , 2006, Journal of medicinal chemistry.
[66] Xiaohua Ma,et al. Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.
[67] R. Shank,et al. Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships. , 1987, Journal of medicinal chemistry.
[68] M. Baccarani,et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. , 2002, The New England journal of medicine.
[69] Boon Chuan Low,et al. Evaluation of Virtual Screening Performance of Support Vector Machines Trained by Sparsely Distributed Active Compounds , 2008, J. Chem. Inf. Model..
[70] Gary K. Schwartz,et al. A Phase II Study of Flavopiridol (Alvocidib) in Combination with Docetaxel in Refractory, Metastatic Pancreatic Cancer , 2009, Pancreatology.
[71] K. Chou,et al. Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. , 2009, Bioorganic & medicinal chemistry.
[72] S. Sherman,et al. Early clinical studies of novel therapies for thyroid cancers. , 2008, Endocrinology and metabolism clinics of North America.
[73] Josep Tabernero,et al. The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents , 2007, Molecular Cancer Research.
[74] S D Kemp,et al. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. , 1995, Science.
[75] Peter J. Parker,et al. HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells , 2008, PloS one.
[76] D. Sacks,et al. IQGAP1 modulates activation of B-Raf , 2007, Proceedings of the National Academy of Sciences.
[77] Barry Sloan,et al. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. , 2008, Current opinion in investigational drugs.
[78] Keith L. Ligon,et al. Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.
[79] Joanna Schwartz,et al. Current combination chemotherapy regimens for metastatic breast cancer. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[80] Keith T Flaherty,et al. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases , 2006, Molecular Cancer Therapeutics.
[81] 出口 靖之,et al. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines , 2007 .
[82] Brian Lord,et al. In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor. , 2008, European journal of pharmacology.
[83] N. Nitta,et al. A combination of cisplatin-eluting gelatin microspheres and flavopiridol enhances anti-tumour effects in a rabbit VX2 liver tumour model. , 2010, The British journal of radiology.
[84] S. Emanuel,et al. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases. , 2005, Cancer research.
[85] Ignacio Wistuba,et al. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion , 2007, Molecular Cancer Therapeutics.
[86] Brian K. Shoichet,et al. Virtual screening of chemical libraries , 2004, Nature.
[87] Yoshua Bengio,et al. Collaborative Filtering on a Family of Biological Targets , 2006, J. Chem. Inf. Model..
[88] David Bates,et al. ZD-6474. AstraZeneca. , 2003, Current opinion in investigational drugs.
[89] E. Vokes,et al. Phase II study of flavopiridol in patients with advanced colorectal cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[90] B. Stockwell,et al. Multicomponent therapeutics for networked systems , 2005, Nature Reviews Drug Discovery.
[91] Ramadevi Sanam,et al. Discovery of novel small-molecule inhibitors of human epidermal growth factor receptor-2: combined ligand and target-based approach. , 2008, Journal of medicinal chemistry.
[92] Hans Briem,et al. Classifying “Kinase Inhibitor‐Likeness” by Using Machine‐Learning Methods , 2005, Chembiochem : a European journal of chemical biology.
[93] Jeffrey D. Goldsmith,et al. Flt-1-Dependent Survival Characterizes the Epithelial-Mesenchymal Transition of Colonic Organoids , 2003, Current Biology.
[94] S Fruehauf,et al. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL – Inhibition of P-glycoprotein function by 17-AAG , 2005, Leukemia.
[95] Neeraj Gupta,et al. Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[96] G. Hortobagyi,et al. Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer , 2006, Nature Clinical Practice Oncology.
[97] Yujia Dai,et al. Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors , 2006, Molecular Cancer Therapeutics.
[98] Pero Melloni,et al. POTENTIAL ANTIDEPRESSANT AGENTS. α-ARYLOXY-BENZYL DERIVATIVES OF ETHANOLAMINE AND MORPHOLINE , 1984 .
[99] Lourdes Santana,et al. Unify QSAR approach to antimicrobials. Part 1: predicting antifungal activity against different species. , 2006, Bioorganic & medicinal chemistry.